Symbols / WHWK $3.59 +0.00%
WHWK Chart
About
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 169.44M |
| Enterprise Value | 23.74M | Income | -20.60M | Sales | 7.14M |
| Book/sh | 2.89 | Cash/sh | 3.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | 23 | IPO | — |
| P/E | — | Forward P/E | -2.99 | PEG | — |
| P/S | 23.71 | P/B | 1.24 | P/C | — |
| EV/EBITDA | -0.21 | EV/Sales | 3.32 | Quick Ratio | 10.04 |
| Current Ratio | 10.26 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.33 | EPS next Y | -1.20 | EPS Growth | — |
| Revenue Growth | -100.00% | Earnings | 2026-05-07 | ROA | -64.66% |
| ROE | -21.82% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -16.01% | Profit Margin | -288.26% | Shs Outstand | 47.20M |
| Shs Float | 19.02M | Short Float | 2.21% | Short Ratio | 7.03 |
| Short Interest | — | 52W High | 4.48 | 52W Low | 1.39 |
| Beta | 0.64 | Avg Volume | 148.68K | Volume | 147.08K |
| Target Price | $5.67 | Recom | Buy | Prev Close | $3.59 |
| Price | $3.59 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.67
Mean price target
2. Current target
$3.59
Latest analyst target
3. DCF / Fair value
$-20.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.59
Low
$4.00
High
$7.00
Mean
$5.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-22 | init | Jones Trading | — → Buy | $7 |
- Inside Whitehawk's 3 next-gen cancer drug conjugates debuting at AACR 2026 - Stock Titan ue, 17 Mar 2026 20
- Wall Street Zen Upgrades Whitehawk Therapeutics (NASDAQ:WHWK) to Hold - MarketBeat Sat, 21 Mar 2026 05
- WHITEHAWK THERAPEUTICS ($WHWK) Releases Q4 2025 Earnings - Quiver Quantitative hu, 12 Mar 2026 12
- Whitehawk Therapeutics Inc PE Ratio (TTM) & PE Ratio (TTM) Charts - WHWK - GuruFocus Mon, 16 Mar 2026 05
- WHWK Stock Price and Chart — NASDAQ:WHWK - TradingView Wed, 15 Oct 2025 07
- Cancer drug developer Whitehawk lines up three March investor talks - Stock Titan hu, 26 Feb 2026 08
- Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026 - ChartMill ue, 17 Mar 2026 20
- Whitehawk Therapeutics (WHWK) Swings To US$0.37 EPS Profit Challenging Bearish Turnaround Skepticism - simplywall.st Fri, 13 Mar 2026 07
- Oppenheimer Sticks to Their Buy Rating for Whitehawk Therapeutics (WHWK) - The Globe and Mail Sat, 14 Mar 2026 12
- Whitehawk Therapeutics Q4 EPS $(0.34) Misses $(0.13) Estimate - Whitehawk Therapeutics (NASDAQ:WHWK) - Benzinga hu, 12 Mar 2026 12
- Whitehawk Therapeutics stock soars after Tempus AI collaboration - Investing.com hu, 16 Oct 2025 07
- Suvretta Capital Management LLC Buys Shares of 3,700,000 Whitehawk Therapeutics, Inc. $WHWK - MarketBeat Sat, 14 Mar 2026 12
- Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Shares Fly 27% But Investors Aren't Buying For Growth - simplywall.st Sat, 17 Jan 2026 08
- Whitehawk Therapeutics (WHWK) CEO sells shares to cover RSU tax - Stock Titan ue, 10 Mar 2026 07
- Whitehawk Therapeutics (WHWK) officer vests 5,000 RSUs, small tax sale - Stock Titan ue, 10 Mar 2026 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 2594 | 8585.0 | — | Sale at price 3.31 per share. | GIACOBELLO SCOTT M | Chief Financial Officer | — | 2026-03-02 00:00:00 | D |
| 1 | 1834 | 6070.0 | — | Sale at price 3.31 per share. | BALL BRYAN | Officer | — | 2026-03-02 00:00:00 | D |
| 2 | 5100 | 16879.0 | — | Sale at price 3.31 per share. | LENNON DAVID JAMES | Chief Executive Officer | — | 2026-03-02 00:00:00 | D |
| 3 | 6750 | nan | — | — | GIACOBELLO SCOTT M | Chief Financial Officer | — | 2026-02-27 00:00:00 | D |
| 4 | 5000 | nan | — | — | BALL BRYAN | Officer | — | 2026-02-27 00:00:00 | D |
| 5 | 16250 | nan | — | — | LENNON DAVID JAMES | Chief Executive Officer | — | 2026-02-27 00:00:00 | D |
| 6 | 1561000 | 3746400.0 | — | Stock Award(Grant) at price 2.40 per share. | DALAL ANUPAM M.D. | Director | — | 2025-03-04 00:00:00 | I |
| 7 | 1666000 | 3998400.0 | — | Stock Award(Grant) at price 2.40 per share. | CASTELEIN CALEY M. | Director | — | 2025-03-04 00:00:00 | I |
| 8 | 100000 | 240000.0 | — | Stock Award(Grant) at price 2.40 per share. | BALL BRYAN | Officer | — | 2025-03-04 00:00:00 | D |
| 9 | 1250000 | 3000000.0 | — | Stock Award(Grant) at price 2.40 per share. | ZHAO BAITENG PH.D. | Director | — | 2025-03-04 00:00:00 | I |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -107.79M | -60.70M | -65.36M | -56.40M |
| TotalUnusualItems | 87.27M | -2.64M | -1.00K | -3.72M |
| TotalUnusualItemsExcludingGoodwill | 87.27M | -2.64M | -1.00K | -3.72M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -20.60M | -63.69M | -65.77M | -60.51M |
| ReconciledDepreciation | 79.00K | 193.00K | 169.00K | 159.00K |
| ReconciledCostOfRevenue | 760.00K | 3.02M | 2.81M | 1.33M |
| EBITDA | -20.52M | -63.34M | -65.36M | -60.12M |
| EBIT | -20.60M | -63.54M | -65.53M | -60.28M |
| NetInterestIncome | 6.23M | 3.77M | 6.17M | 2.17M |
| InterestExpense | 0.00 | 154.00K | 231.00K | 230.00K |
| InterestIncome | 6.23M | 3.92M | 6.40M | 2.40M |
| NormalizedIncome | -107.87M | -61.05M | -65.76M | -56.79M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -20.60M | -63.69M | -65.77M | -60.51M |
| TotalExpenses | 121.55M | 90.80M | 96.29M | 74.17M |
| TotalOperatingIncomeAsReported | -114.40M | -67.46M | -71.93M | -62.68M |
| DilutedAverageShares | 61.89M | 27.03M | 26.92M | 22.51M |
| BasicAverageShares | 61.89M | 27.03M | 26.92M | 22.51M |
| DilutedEPS | -0.33 | -2.36 | -2.44 | -2.69 |
| BasicEPS | -0.33 | -2.36 | -2.44 | -2.69 |
| DilutedNIAvailtoComStockholders | -20.60M | -63.69M | -65.77M | -60.51M |
| NetIncomeCommonStockholders | -20.60M | -63.69M | -65.77M | -60.51M |
| PreferredStockDividends | 647.00K | |||
| NetIncome | -20.60M | -63.69M | -65.77M | -60.51M |
| NetIncomeIncludingNoncontrollingInterests | -20.60M | -63.69M | -65.77M | -60.51M |
| NetIncomeContinuousOperations | -20.60M | -63.69M | -65.77M | -60.51M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -20.60M | -63.69M | -65.77M | -60.51M |
| OtherIncomeExpense | 87.57M | -2.64M | -1.00K | -3.72M |
| OtherNonOperatingIncomeExpenses | 302.00K | 1.58M | ||
| SpecialIncomeCharges | 87.27M | -2.64M | 0.00 | -3.72M |
| GainOnSaleOfBusiness | 87.27M | 0.00 | ||
| OtherSpecialCharges | -196.00K | |||
| ImpairmentOfCapitalAssets | 0.00 | 3.72M | 74.16M | |
| RestructuringAndMergernAcquisition | 0.00 | 2.64M | 0.00 | |
| GainOnSaleOfSecurity | 5.00K | -4.00K | -1.00K | |
| NetNonOperatingInterestIncomeExpense | 6.23M | 3.77M | 6.17M | 2.17M |
| InterestExpenseNonOperating | 0.00 | 154.00K | 231.00K | 230.00K |
| InterestIncomeNonOperating | 6.23M | 3.92M | 6.40M | 2.40M |
| OperatingIncome | -114.40M | -64.82M | -71.93M | -58.96M |
| OperatingExpense | 120.78M | 87.78M | 93.48M | 72.84M |
| OtherOperatingExpenses | -120.00K | |||
| ResearchAndDevelopment | 90.96M | 51.03M | 48.93M | 32.66M |
| SellingGeneralAndAdministration | 29.82M | 36.75M | 44.55M | 40.18M |
| GeneralAndAdministrativeExpense | 18.51M | |||
| OtherGandA | 18.51M | |||
| GrossProfit | 6.38M | 22.96M | 21.55M | 13.88M |
| CostOfRevenue | 760.00K | 3.02M | 2.81M | 1.33M |
| TotalRevenue | 7.14M | 25.98M | 24.35M | 15.22M |
| OperatingRevenue | 7.14M | 25.98M | 24.35M | 15.22M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 47.15M | 24.68M | 24.55M | 24.44M |
| ShareIssued | 47.15M | 24.68M | 24.55M | 24.44M |
| TotalDebt | 0.00 | 833.00K | 1.27M | 1.66M |
| TangibleBookValue | 136.31M | 52.48M | 105.19M | 158.38M |
| InvestedCapital | 136.31M | 52.48M | 105.19M | 158.38M |
| WorkingCapital | 134.49M | 44.21M | 98.19M | 161.19M |
| NetTangibleAssets | 136.31M | 52.48M | 105.19M | 158.38M |
| CapitalLeaseObligations | 0.00 | 833.00K | 1.27M | 1.66M |
| CommonStockEquity | 136.31M | 52.48M | 105.19M | 158.38M |
| TotalCapitalization | 136.31M | 52.48M | 105.19M | 158.38M |
| TotalEquityGrossMinorityInterest | 136.31M | 52.48M | 105.19M | 158.38M |
| StockholdersEquity | 136.31M | 52.48M | 105.19M | 158.38M |
| GainsLossesNotAffectingRetainedEarnings | 120.00K | 16.00K | 27.00K | -115.00K |
| OtherEquityAdjustments | 120.00K | 16.00K | 27.00K | -115.00K |
| RetainedEarnings | -353.25M | -332.65M | -268.96M | -203.20M |
| AdditionalPaidInCapital | 489.44M | 385.11M | 374.13M | 361.69M |
| CapitalStock | 4.00K | 2.00K | 2.00K | 2.00K |
| CommonStock | 4.00K | 2.00K | 2.00K | 2.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 14.52M | 17.84M | 27.23M | 25.86M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 0.00 | 767.00K | 833.00K | 7.02M |
| OtherNonCurrentLiabilities | 202.00K | |||
| DuetoRelatedPartiesNonCurrent | 0.00 | 5.76M | 5.76M | |
| TradeandOtherPayablesNonCurrent | 0.00 | 0.00 | 0.00 | |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 565.00K | 833.00K | 1.27M |
| LongTermCapitalLeaseObligation | 0.00 | 565.00K | 833.00K | 1.27M |
| CurrentLiabilities | 14.52M | 17.07M | 26.39M | 18.84M |
| CurrentDebtAndCapitalLeaseObligation | 268.00K | 434.00K | 394.00K | 131.00K |
| CurrentCapitalLeaseObligation | 0.00 | 268.00K | 434.00K | 394.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 3.16M | 64.00K | 3.08M | 5.46M |
| PayablesAndAccruedExpenses | 11.36M | 16.74M | 22.88M | 12.98M |
| CurrentAccruedExpenses | 10.44M | 14.58M | 11.22M | 9.46M |
| Payables | 917.00K | 2.16M | 11.65M | 3.52M |
| OtherPayable | 5.76M | |||
| DuetoRelatedPartiesCurrent | 5.76M | 0.00 | 258.00K | |
| AccountsPayable | 917.00K | 2.16M | 5.90M | 3.52M |
| TotalAssets | 150.83M | 70.32M | 132.42M | 184.24M |
| TotalNonCurrentAssets | 1.82M | 9.03M | 7.84M | 4.21M |
| OtherNonCurrentAssets | 1.81M | 1.40M | 1.87M | 2.18M |
| GoodwillAndOtherIntangibleAssets | 0.00 | 3.81M | ||
| OtherIntangibleAssets | 3.81M | |||
| NetPPE | 3.00K | 7.63M | 5.97M | 2.03M |
| AccumulatedDepreciation | -374.00K | -463.00K | -270.00K | -101.00K |
| GrossPPE | 377.00K | 8.10M | 6.24M | 2.13M |
| Leases | 0.00 | 133.00K | 129.00K | 129.00K |
| ConstructionInProgress | 0.00 | 6.59M | 4.39M | 77.00K |
| OtherProperties | 51.00K | 25.00K | 1.52M | 557.00K |
| MachineryFurnitureEquipment | 377.00K | 535.00K | 529.00K | 403.00K |
| BuildingsAndImprovements | 0.00 | 787.00K | 1.17M | 1.52M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 149.01M | 61.29M | 124.59M | 180.03M |
| OtherCurrentAssets | 3.32M | 2.84M | 3.83M | 3.75M |
| PrepaidAssets | 2.28M | |||
| Inventory | 0.00 | 5.31M | 6.43M | 1.86M |
| FinishedGoods | 0.00 | 1.78M | 421.00K | 917.00K |
| WorkInProcess | 0.00 | 0.00 | 1.37M | 0.00 |
| RawMaterials | 0.00 | 3.53M | 4.64M | 944.00K |
| Receivables | 0.00 | 5.90M | 5.49M | 1.86M |
| AccountsReceivable | 0.00 | 5.90M | 5.49M | 1.86M |
| AllowanceForDoubtfulAccountsReceivable | -100.00K | -200.00K | ||
| GrossAccountsReceivable | 6.00M | 5.69M | ||
| CashCashEquivalentsAndShortTermInvestments | 145.70M | 47.24M | 108.84M | 172.56M |
| OtherShortTermInvestments | 108.13M | 18.57M | 45.96M | 133.54M |
| CashAndCashEquivalents | 37.57M | 28.67M | 62.89M | 39.02M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -97.98M | -61.20M | -63.63M | -50.08M |
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 100.00M | 0.00 | 0.00 | 72.50M |
| CapitalExpenditure | -552.00K | -1.65M | -3.97M | -444.00K |
| InterestPaidSupplementalData | 0.00 | 211.00K | 230.00K | 230.00K |
| EndCashPosition | 37.57M | 28.73M | 62.95M | 39.08M |
| BeginningCashPosition | 28.73M | 62.95M | 39.08M | 148.99M |
| ChangesInCash | 8.83M | -34.22M | 23.87M | -109.91M |
| FinancingCashFlow | 94.38M | 130.00K | 326.00K | 72.62M |
| CashFlowFromContinuingFinancingActivities | 94.38M | 130.00K | 326.00K | 72.62M |
| NetOtherFinancingCharges | -5.70M | -16.00K | -160.00K | -659.00K |
| ProceedsFromStockOptionExercised | 75.00K | 146.00K | 486.00K | 779.00K |
| CashDividendsPaid | 0.00 | -4.41M | ||
| NetCommonStockIssuance | 100.00M | 0.00 | 0.00 | 72.50M |
| CommonStockIssuance | 100.00M | 0.00 | 0.00 | 72.50M |
| NetIssuancePaymentsOfDebt | 0.00 | |||
| NetLongTermDebtIssuance | 0.00 | |||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | 11.89M | 25.20M | 83.21M | -132.89M |
| CashFlowFromContinuingInvestingActivities | 11.89M | 25.20M | 83.21M | -132.89M |
| NetInvestmentPurchaseAndSale | -88.84M | 26.86M | 87.18M | -132.44M |
| SaleOfInvestment | 59.84M | 63.34M | 151.62M | 12.75M |
| PurchaseOfInvestment | -148.69M | -36.48M | -64.44M | -145.19M |
| NetBusinessPurchaseAndSale | 101.29M | 0.00 | 0.00 | 25.20M |
| SaleOfBusiness | 101.29M | 0.00 | 0.00 | 29.70M |
| PurchaseOfBusiness | 0.00 | -4.50M | ||
| NetPPEPurchaseAndSale | -552.00K | -1.65M | -3.97M | -444.00K |
| PurchaseOfPPE | -552.00K | -1.65M | -3.97M | -444.00K |
| OperatingCashFlow | -97.43M | -59.55M | -59.66M | -49.64M |
| CashFlowFromContinuingOperatingActivities | -97.43M | -59.55M | -59.66M | -49.64M |
| ChangeInWorkingCapital | 1.93M | -6.05M | -3.40M | -1.82M |
| ChangeInOtherCurrentLiabilities | -291.00K | -310.00K | -502.00K | -291.00K |
| ChangeInOtherCurrentAssets | -438.00K | 518.00K | 518.00K | 437.00K |
| ChangeInPayablesAndAccruedExpense | 3.92M | -9.77M | -132.00K | 3.22M |
| ChangeInPayable | -90.00K | |||
| ChangeInAccountPayable | 8.29M | |||
| ChangeInPrepaidAssets | -434.00K | 2.81M | 3.60M | -1.46M |
| ChangeInInventory | 170.00K | 1.12M | -3.27M | -1.86M |
| ChangeInReceivables | -1.00M | -415.00K | -3.63M | -1.86M |
| ChangesInAccountReceivables | -1.00M | -415.00K | -3.63M | -1.86M |
| OtherNonCashItems | 74.00K | 460.00K | 519.00K | 382.00K |
| StockBasedCompensation | 9.87M | 10.84M | 11.95M | 9.64M |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | -1.58M | ||
| AssetImpairmentCharge | 0.00 | 3.72M | 74.16M | |
| AmortizationOfSecurities | -1.53M | -1.30M | -3.14M | -1.22M |
| DepreciationAmortizationDepletion | 79.00K | 193.00K | 169.00K | 159.00K |
| DepreciationAndAmortization | 79.00K | 193.00K | 169.00K | 159.00K |
| OperatingGainsLosses | -87.27M | -196.00K | ||
| GainLossOnSaleOfBusiness | -87.27M | |||
| NetIncomeFromContinuingOperations | -20.60M | -63.69M | -65.77M | -60.51M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|